Literature DB >> 6181087

Polyclonal and antigen-specific B-cell responses in patients with common variable immunodeficiency.

S G Pahwa, M K Hoffman, R N Pahwa, R A Good.   

Abstract

Antigen-specific antibody responses were investigated in 32 hypogammaglobulinemic patients with common variable immunodeficiency following in vitro sensitization of their peripheral blood lymphocyte cultures with sheep red blood-cell determinants. Anti-sheep red blood-cell antibody-secreting cells were quantitated in a hemolytic plaque assay. Amplification of T-cell help was achieved with the use of the T-cell mitogen concanavalin A or allogeneic irradiated T cells. Four patients groups, A through D, were identified. Group A was comprised of 10 patients whose cultured lymphocyte readily developed into antibody secreting cells. Cultures of 9 patients (Group B) responded suboptimally, but were enhanced following mitogen activation of autologous or exogenous T cells, and those of 7 patients (Group C) responded only when help was amplified. In 7 patients (Group D), no responses were elicited. On the simultaneous assessment of pokeweed mitogen-driven polyclonal generation of immunoglobulin-secreting cells, only 10 responders, all from groups A and B, were identified. Our observations indicate that the majority of patients with common variable immunodeficiency possesses B cells capable of producing antibody in vitro. The ability of some patients' B cells to respond only in the antigen-specific assay while failing to do so in pokeweed mitogen-stimulated cultures suggests that these two reactions are not identical in their activation pathways.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181087     DOI: 10.1007/bf00915223

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  26 in total

1.  Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A.

Authors:  S W Kessler
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

2.  Failure of heavy chain glycosylation of IgG in some patients with common, variable agammaglobulinemia.

Authors:  F Ciccimarra; F S Rosen; E Schneeberger; E Merler
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

Review 3.  Control of B-cell differentiation by macrophages.

Authors:  M K Hoffmann
Journal:  Ann N Y Acad Sci       Date:  1979       Impact factor: 5.691

4.  Artifactual plaque formation in vitro and in vivo to passive transfer of specific antibody.

Authors:  A V Muchmore; I Koski; N Dooley; R M Blaese
Journal:  J Immunol       Date:  1976-04       Impact factor: 5.422

5.  Antigen-specific induction and regulation of antibody synthesis in cultures of human peripheral blood mononuclear cells.

Authors:  M K Hoffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

6.  Influence of human thymocytes on B-lymphocyte differentiation in man.

Authors:  S Pahwa; L Shou; R Pahwa; E Smithwick; R A Good
Journal:  Cell Immunol       Date:  1979-05       Impact factor: 4.868

7.  A human monocyte function test: release of B-cell differentiation factor (BDF).

Authors:  M Finelt; M K Hoffmann
Journal:  Clin Immunol Immunopathol       Date:  1979-03

8.  Defective cellular immune response in vitro in common variable immunodeficiency.

Authors:  S Cunningham-Rundles; C Cunningham-Rundles; F P Siegal; S Gupta; E M Smithwick; C Kosloff; R A Good
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

9.  Plaque Formation in Agar by Single Antibody-Producing Cells.

Authors:  N K Jerne; A A Nordin
Journal:  Science       Date:  1963-04-26       Impact factor: 47.728

10.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

View more
  8 in total

1.  Accelerated expression of secreted alpha-chain gene in anaphylactoid purpura.

Authors:  N Kondo; K Kasahara; S Shinoda; T Orii
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

2.  Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin.

Authors:  N Kondo; T Ozawa; K Mushiake; F Motoyoshi; T Kameyama; K Kasahara; H Kaneko; M Yamashina; Y Kato; T Orii
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

3.  Recombinant interleukin 2 therapy in severe combined immunodeficiency disease.

Authors:  R Pahwa; T Chatila; S Pahwa; C Paradise; N K Day; R Geha; S A Schwartz; H Slade; N Oyaizu; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

4.  Clinical and immunologic analyses of 103 patients with common variable immunodeficiency.

Authors:  C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

5.  B-cell function in common variable immunodeficiency: suppression of in vitro anti-sheep erythrocytes antibody production by T cells and monocytes.

Authors:  S Pollack; Y Reisner; B Koziner; R A Good; M K Hoffman
Journal:  Immunology       Date:  1985-01       Impact factor: 7.397

6.  Rescue of IgM, IgG, and IgA production in common varied immunodeficiency by T cell-independent stimulation with Epstein-Barr virus.

Authors:  G Jeong; P Ralph; I Nakoinz; O Saiki; C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1985-03       Impact factor: 8.317

7.  Specific anti-influenza virus antibody production in vitro by lymphocytes from a subset of patients with hypogammaglobulinemia.

Authors:  R Yarchoan; H S Schneider; B B Wray; D L Nelson
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

8.  Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.

Authors:  S Pahwa; R Pahwa; C Saxinger; R C Gallo; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.